Serum Metabolomics Benefits Discrimination Kidney Disease Development in Type 2 Diabetes Patients.

ABSTRACT:

Background

Diabetic kidney disease (DKD) is the primary cause of end-stage renal disease, raising a considerable burden worldwide. Recognizing novel biomarkers by metabolomics can shed light on new biochemical insight to benefit DKD diagnostics and therapeutics. We hypothesized that serum metabolites can serve as biomarkers in the progression of DKD.

Methods

A cross-sectional study of 1,043 plasma metabolites by untargeted LC/MS among 89 participants identified associations between proteinuria severity and metabolites difference. Pathway analysis from differently expressed metabolites was used to determine perturbed metabolism pathways. The results were replicated in an independent, cross-sectional cohort of 83 individuals. Correlation and prediction values were used to exam

SUBMITTER: Peng X 

PROVIDER: S-EPMC9126316 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature